Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer

Cancer Clinical Trial

Official title:

A Phase 1 With Expansion Cohort, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenously Infused IT-141 in Subjects With Recurrent or Refractory Solid Tumors

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03096340
• Other study ID #: IT141-001
• Status: Terminated
• Phase: Phase 1
• Start date: March 23, 2017
• Est. completion date: November 26, 2019

Study information

• Verified date: January 2020
• Source: Intezyne Technologies, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

IT141 is a novel nanoparticle formulation of SN-38, the active metabolite of irinotecan, and is intended to deliver more drug to the tumor with reduced toxicity on normal tissues. The study is designed to determine the maximum tolerated dose (MTD) of IT-141, and to investigate pharmacokinetic (PK) parameters and possible pharmacodynamics (PD) relationships. Patients will also be monitored for any response to therapy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 10
• Est. completion date: November 26, 2019
• Est. primary completion date: August 22, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must be 18 years of age or older.
• Must be males or non-pregnant females who agree to comply with applicable contraceptive requirements of the protocol.
• Must have a histologically or cytologically confirmed, incurable malignancy, for which further standard treatment is not currently available.
• Must have measurable or evaluable disease during the dose escalation phase (measurable disease is preferred for the expanded cohort after MTD is reached).
• Must have an anticipated survival of at least 12 weeks.
• Must be fully informed regarding their illness and the investigational nature of the study protocol, and must sign an Institutional Review Board (IRB) approved Informed Consent Form (ICF).
• Must be ambulatory, with an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.
• Must have adequate organ function, as defined by the following:
• Hematologic: ANC 1.5 x 109/L, Hgb = 9.0 g/dL and platelet count 100 x 109/L (platelet count > 75 x 109/L if documented evidence of bone marrow involvement).
• Hepatic: Total bilirubin 1.5 x ULN; transaminases = 2.5 x ULN (may be up to 5 x ULN if clearly due to liver metastases); prothrombin time (PT) and partial thromboplastin time (PTT) < 2 x (ULN).
• Renal: Serum creatinine 1.5 x ULN or creatinine clearance 60 mL/min.
• Must be on stable doses of any drugs affecting hepatic drug metabolism or renal drug excretion (e.g. non-steroidal anti-inflammatory drugs, corticosteroids, barbiturates, diphenylhydantoin, narcotic analgesics, probenecid). Such drugs should not be initiated less than 30 days prior to Baseline/C1D1 or at any time during study participation. Whenever possible, narcotic analgesic doses should be stable within 30 days prior to study entry and during the first cycle of therapy.
• Must be recovered from any reversible side effects of prior therapy (e.g. no major surgery, no antineoplastic or experimental therapy, or no significant radiation therapy to hematopoietic sites within 4 weeks of Baseline/C1D1, and no nitrosoureas or nitrogen mustards within 6 weeks of Baseline/C1D1)
• Must understand and be able, willing, and likely to fully comply with study procedures and restrictions.

Exclusion Criteria:

• Current or recurrent disease that could affect the action or disposition of IT-141, or clinical or laboratory assessments.
• Subjects with UGT1A1*28 polymorphisms.
• Current or relevant previous history of serious, severe or unstable (acute or progressive) physical or psychiatric illness, including any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the IP or procedures.
• Primary brain tumors or known brain metastasis unless clinically stable and on stable or reducing doses of steroids.
• Frequent vomiting.
• Recent history of unintentional weight loss > 10% of current body weight in the past 3 months.
• Ongoing radiation therapy, chemotherapy, or hormonal therapy. Point radiation to a site of bone pain will be allowed.
• Current (within 1 week of Screening) or regular use of any medication (including over-the-counter (OTC), herbal or homeopathic preparations) that could improve or worsen the cancer being studied, or could affect the action or disposition of IT-141, or its clinical or laboratory assessment; e.g. Coumadin therapy, due to high competitive protein binding. Subjects taking ANY supplemental IRON, i.e., therapeutic or as part of a multivitamin regimen, are excluded from this study, whether prescribed or self-medicated.
• Concomitant use of a UGT1A1 inhibitor, such as idinavir, atazanavir and sorafenib, throughout the study period.
• Known or suspected intolerance or hypersensitivity to IT-141 or any of the stated ingredients.
• History of alcohol or other substance abuse within the last year.
• History of use of another IP within the last 4 weeks prior to enrollment.
• Female subjects who are pregnant or lactating, including females with a positive pregnancy test at screening.
• Previous enrollment in this study, followed by withdrawal for any reason.
• Known HIV-positive subjects on combination anti-retroviral therapy due to the potential for PK interactions with the study agent.
• Evidence of ischemia or myocardial infarction within the past 6 months, or any significant abnormality on ECG.
• A QTc interval outside of normal. (Normal: < 450 msec for males and < 460 msec for females)

Related Conditions & MeSH terms

• Cancer
• Neoplasms
• Recurrent Solid Tumors
• Refractory Solid Tumors
• Tumors

Intervention

Drug:
• IT-141
Escalating doses administered in mg/m2, IV (in the vein) on days 1 and 15 of each 28 day cycle until progression or unacceptable toxicity develops.

Locations

Country	Name	City	State
United States	Mary Crowley Cancer Research Centers - Medical City	Dallas	Texas
United States	Seattle Cancer Care Alliance	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Intezyne Technologies, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Bakewell SJ, Carie A, Costich TL, Sethuraman J, Semple JE, Sullivan B, Martinez GV, Dominguez-Viqueira W, Sill KN. Imaging the delivery of drug-loaded, iron-stabilized micelles. Nanomedicine. 2017 May;13(4):1353-1362. doi: 10.1016/j.nano.2017.01.009. Epub 2017 Jan 20. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Overall Survival		18 months
Other	Progression-free Survival		18 months
Other	Time to progression		18 months
Other	Disease Control Rate		2 years
Other	MRI imaging for biodistribution of IT-141		18 months
Other	Presence of cfDNA		2 years
Other	Presence of exosomes		2 years
Primary	Maximum tolerated dose of IT-141 administered once every 2 weeks in patients with refractory solid tumors		18 months
Secondary	Adverse event profiles according to the Common Toxicity Criteria for Adverse Events (CTCAE, ver. 4.03)		18 months
Secondary	Objective response rate based on RECIST		18 months
Secondary	Area under the plasma concentration versus time curve (AUC) of SN-38 and SN-38G		18 months
Secondary	Maximum plasma concentration (Cmax) of SN-38 and SN-38G		18 months
Secondary	Time to Cmax (Tmax) of SN-38 and SN-38G		18 months
Secondary	Elimination rate constant of SN-38 and SN-38G		18 months
Secondary	Terminal half-life (t1/2) of SN-38 and SN-38G		18 months
Secondary	Total plasma clearance (CL) of SN-38 and SN-38G		18 months
Secondary	Volume of distribution (Vz) of SN-38 and SN-38G		18 months